title: [Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
abstract: Management of febrile neutropenia (FN) is important for the safety of patients undergoing outpatient chemotherapy. Oral antimicrobials are usually prescribed as the initial treatment for FN, and outpatients are instructed to begin medication prior to chemotherapy. However, the effectiveness and safety of the use of these oral antibiotics have not yet been established. In this study, we investigated the effectiveness and safety of levofloxacin hydrate (LVFX) for breast cancer patients with FN, and the factors associated with the onset of FN in 134 breast cancer patients who underwent chemotherapy including the anticancer drug anthracycline (total, 513 courses), in an outpatient chemotherapy department. The effectiveness and safety of LVFX were defined respectively as defervescence within 5 days, and the appearance of side effects such as diarrhea and rashes. Fever was observed in 89 (66%) of the 134 patients, and during 164 (32%) of 513 courses. Defervescence was observed with the LVFX medication in 149 (93%) of 160 courses. The primary side effect was the development of rashes, and only 2 (1%) of the 160 courses were discontinued. Onset of stomatitis during chemotherapy was observed as a factor of FN (odds ratio: 1.36, p<0.05). Our results suggest that the use of LVFX according to the patients' discretion might be an effective and safe option for the management of FN during outpatient chemotherapy.
authors.affiliation: Dept. of Pharmacy, Iwate Medical University Hospital.
authors.forename: Manato
authors.initials: M
authors.lastname: Inagaki
authors.forename: Junya
authors.initials: J
authors.lastname: Sato
authors.forename: Satoru
authors.initials: S
authors.lastname: Nihei
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kashiwaba
authors.forename: Kenzo
authors.initials: K
authors.lastname: Kudo
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D064147:Febrile Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D064704:Levofloxacin / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D064704:Levofloxacin